Latest Lapatinib Stories
Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando beginning May 29.
An oral medication could help some patients with inflammatory breast cancer.
GlaxoSmithKline PLC has petitioned the United States and Europe for permission in to market an already accessible breast-cancer drug as a first-line treatment option.
LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib).
Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
Nonhormonal chemotherapy treatment regimens, including anthracycline-based regimens and taxanes have been shown to improve overall survival in women with metastatic or recurrent inoperable breast cancer over the last 35 years.Researchers at the University of Ioannina School of Medicine in Greece performed a meta-analysis of 128 clinical trials that included 148 comparisons of breast cancer treatment regimens."Our meta-analysis quantifies the progress achieved in the treatment of advanced...
SAN ANTONIO, Dec. 15 /PRNewswire/ -- Two leading cancer physicians and researchers affiliated with US Oncology Research gave oral presentations at the 2008 San Antonio Breast Cancer Symposium.
A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say.
A breast cancer chemotherapy drug shows benefits to one type of breast cancer but not for another type, U.S. researchers said.
CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology.
- a slit in a tire to drain away surface water and improve traction.